KEI and UACT comments on NIH license to GLG Pharma over a STAT3 Inhibitor “in all proliferative diseases” (and NIH Response)
(UPDATE: The NIH provided a response to our comments on June 18, 2019) On June 7, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 23798, on the “Prospective Grant of an Exclusive Patent License: The… Continue Reading